ACCP collaborates with ASHP on Oncology Pharmacy activities.

ASHP members, please visit www.rxcertifications.org to receive member pricing.

• Series Overview
• Program Content
• Faculty and Reviewers
• Financial Relationship Disclosures
• Target Audience and Learning Objectives
• Continuing Pharmacy Education Credit
• Specialty Recertification Credit
• Technical Requirements
• Commercial Support
• Fees

The 2022 ACCP/ASHP BCOP Clinical Sessions are part of the professional development programs for recertification of the Board Certified Oncology Pharmacist approved by the Board of Pharmacy Specialties (BPS) and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP).

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants' skills and abilities to critically evaluate the scientific evidence and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

Release date: December 14, 2022
Specialty Recertification credit expiration date: December 12, 2023
ACPE credit expiration date: December 14, 2025

The 2022 ACCP/ASHP BCOP Clinical Sessions are offered in two presentations. The first presentation is focused on the use of ctDNA and MRD in oncology and the second presentation is focused on updates in treatments of hematologic disorders.

BCOP Clinical Session
Taking a Deeper Dive: The Utilization of ctDNA and Minimal Residual Disease (MRD) to Assess Anticancer Therapeutic Response in Cancer
This session is designed to provide the necessary background and data that supports the use of ctDNA and MRD in oncology. Circulating tumor DNA (ctDNA), a form of liquid biopsy, is a noninvasive method that has become a reliable tool in oncology, both in solid tumors and hematologic malignancies. Over 850 clinical trials are currently recruiting for studies involving the use of ctDNA in solid tumor malignancies and over 1200 clinical trials involving the use of MRD in hematologic malignancies. The use of ctDNA and MRD is transforming how we detect, monitor, and determine treatment across a variety of malignancies. The increasing integration of ctDNA in clinical practice has been seen in the most common solid and hematologic malignancies and is therefore vital for oncology pharmacists to understand the data to support current and future applications of ctDNA and minimal residual disease (MRD).

BCOP Clinical Session
The Alphabet Soup of Hematologic Disorders: Background and Treatment Updates in ITP, TTP, HUS, and DIC
This session will provide a foundation for the basic pathophysiology, etiology, and diagnosis of hematologic disorders including immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC). The critical role of the pharmacist in the treatment of each disease state will be elucidated. The context of these disorders in the setting of COVID-19 and vaccine-associated sequelae will be explored. Pharmacists and pharmacy learners who do not have expertise in Hematology practice will gain confidence in their diagnosis and management skills. Additionally, this session is meant to offer late-breaking updates in the treatment of hematologic disorders for Hematology/Oncology pharmacists in practice.

Taking a Deeper Dive: The Utilization of ctDNA and Minimal Residual Disease (MRD) to Assess Anticancer Therapeutic Response in Cancer

	Caitlyn L. Crawford, Pharm.D., BCOP Hematology/Oncology Clinical Pharmacy Specialist - Multiple Myeloma Atrium Wake Forest Baptist Winston-Salem, North Carolina
	Sandra Cuellar, Pharm.D., BCOP Clinical Associate Professor University of Illinois Medical Center Clinical Oncology Pharmacist University Illinois at Chicago Chicago, Illinois
	David L. DeRemer, Pharm.D., FCCP, BCOP Clinical Professor Assistant Director of Experimental Therapeutics University of Florida College of Pharmacy UF Health Cancer Center Gainesville, Florida

The Alphabet Soup of Hematologic Disorders: Background and Treatment Updates in ITP, TTP, HUS, and DIC

	Sebastian Cerdena, Pharm.D., BCOP Oncology Clinical Pharmacy Specialist Barnes Jewish Hospital Saint Louis, Missouri
	Kathryn Dane, Pharm.D., BCPS Clinical Pharmacy Specialist – Benign Hematology and Cardiology Co-Director – Hemostatic and Antithrombotic Stewardship Program The Johns Hopkins Hospital Baltimore, Maryland
	Sarah Maryon Hayes, Pharm.D., BCOP Hematology/Oncology Clinical Pharmacy Specialist North Memorial Health Care Robbinsdale, Minnesota

• Nada Alsuhebany, PharmD, BCOP
• Ashley L. Johns, Pharm.D., M.S., BCOP
• Kayleigh Marx, Pharm.D., BCOP
• Kelsey Zielke, Pharm.D., BCPS, BCOP

Disclosures 

Target Audience
These recertification activities are intended for the Board-Certified Oncology Pharmacist® (BCOP) and those interested in the use of ctDNA and MRD in oncology and updates in treatments of hematologic disorders.

Learning Objectives
Learning Objectives 

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

BCOP Clinical Session
Taking a Deeper Dive: The Utilization of ctDNA and Minimal Residual Disease (MRD) to Assess Anticancer Therapeutic Response in Cancer
Activity Number: 0217-9999-22-070-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

BCOP Clinical Session
The Alphabet Soup of Hematologic Disorders: Background and Treatment Updates in ITP, TTP, HUS, and DIC
Activity Number: 0217-9999-22-071-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

Methods and CE Requirements

Continuing Pharmacy Education Credit

To be eligible to earn continuing pharmacy education credit, learners must purchase the product, review all content, successfully complete, submit and pass the web-based posttest associated with each module within the course by December 14, 2025. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

National Association of Boards of Pharmacy - CPE Monitor Service

Provided through the collaborative efforts of the National Association of Boards of Pharmacy (NABP), the Accreditation Council for Pharmacy Education (ACPE), and ACPE-accredited providers, the CPE Monitor Service allows you to electronically keep track of continuing pharmacy education (CPE) credits from ACPE-accredited providers. ACPE-accredited providers, like ACCP, are responsible for transmitting this information to NABP to be stored in the CPE Monitor system. Statements of credit will be available at CPE Monitor, nabp.pharmacy/cpe-monitor-service/, within 2–3 business days after completion of this activity. For more information on CPE Monitor please visit nabp.pharmacy/cpe-monitor-service/.

To transfer these credits to CPE Monitor on your behalf your NABP e-Profile ID Number and date of birth must be listed on your ACCP account. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Some international pharmacists do not use the CPE Monitor service. To verify or update this information in your ACCP account, visit Licensure/Certification. Check the box “I am an international pharmacist or I am not licensed to practice in the United States, and do not have an NABP e-Profile ID.” Be sure to save your changes at the bottom of the page.

To be eligible to earn BCOP recertification credit, participants must purchase the recertification version of this course, review all content, successfully complete, submit and pass the Web-based posttest associated with each module by December 12, 2023. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

The passing point to earn BCOP recertification credit is based on an expert analysis of the assessment items in each posttest module. Any posttest submitted before the Specialty Recertification Credit posttest deadline that meets this passing point will earn BCOP recertification credits. These credits will be assigned as of the date of test submission. For statements of recertification credit, visit www.bpsweb.org.

All participants must have a Board of Pharmacy Specialties (BPS) board certification credential number, BPS ID Number, and a BPS expiration date on file with ACCP for reporting purposes. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Questions regarding the number of hours required for BCOP recertification should be directed to BPS at (202) 946-5026 or www.bpsweb.org.

• Internet browser
• Adobe Reader (available free)

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.